20:31 , Jan 18, 2019 |  BC Week In Review  |  Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
23:28 , Jan 17, 2019 |  BC Extra  |  Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
18:00 , Sep 28, 2018 |  BC Week In Review  |  Company News

Novartis to cut Swiss, U.K. jobs to adapt manufacturing

Novartis AG (NYSE:NVS; SIX:NOVN) revealed restructuring plans that could remove a net of up to 1,700 Swiss-based jobs over four years as the pharma continues to evolve its business services organization and manufacturing strategy, spokesperson...
13:05 , Sep 14, 2018 |  BC Week In Review  |  Company News

Aurobino gains Novartis's U.S. dermatology and general U.S. oral solids portfolio

Novartis AG (NYSE:NVS; SIX:NOVN) said it will sell its Sandoz U.S. dermatology business and generic oral solids portfolio to Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) for $900 million in cash. Novartis is also eligible for $100...
17:27 , May 11, 2018 |  BC Extra  |  Company News

Report: Fosun in bid for $2B in Novartis assets

Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) and Novartis AG (NYSE:NVS; SIX:NOVN) declined to comment on a report that Fosun is a shortlisted bidder for a portfolio of Novartis' assets, including the pharma’s U.S....
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Actavis, Aurobindo deal

Aurobindo completed its acquisition of Actavis' generics commercial operations in seven Western European markets in a deal valued at about €30 million ($41.3 million) (see BioCentury, Jan. 27). Actavis plc (NYSE:ACT), Dublin, Ireland   Aurobindo...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Actavis, Aurobindo deal

Aurobindo will acquire Actavis' generics commercial operations in seven Western European markets in a deal valued at about €30 million ($40.7 million). The companies said closing of the deal is conditional on antitrust approvals and...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

Efavirenz/lamivudine/tenofovir disoproxil fumarate regulatory update

Aurobindo said late last month that FDA granted tentative approval to efavirenz/lamivudine/tenofovir disoproxil fumarate tablets alone or in combination with other antiretrovirals to treat HIV-1 infection. The fixed-dose combination of 600 mg efavirenz, 300 mg...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Company News

Sun Pharmaceutical, Teva, Apotex, AstraZeneca, Aurobindo, Cobalt Laboratories Inc., Glenmark, Mylan, Novartis, Par Pharmaceutical, Torrent, Watson, Brigham and

The U.S. Court of Appeals for the Federal Circuit upheld a lower court decision finding that the U.S. substance patent covering AstraZeneca's cardiovascular drug Crestor rosuvastatin is valid and enforceable. In 2010, the U.S. District...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

Singulair montelukast regulatory update

FDA approved ANDAs for generic versions of Merck's Singulair montelukast to control asthma symptoms and to help relieve symptoms of indoor and outdoor allergies. Merck markets Singulair to treat asthma and allergic rhinitis, and to...